임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
60건 표시 (상위 60건)
- 해당없음완료· Respiratory SymptomsGCWB1001 Evaluates the Effectiveness and Safety of Respiratory Health
리드: GC녹십자
- 2상완료· Autoimmune EncephalitisSafety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:
리드: GC녹십자
- 4상완료· Kawasaki DiseaseStudy of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease
리드: GC녹십자
- 4상완료· Renal TransplantIVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies
협력: GC녹십자
- 1상완료· Herpes ZosterSafety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects
협력: GC녹십자
- 2상완료· Influenza, HumanA Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects
리드: GC녹십자
- 1/2상완료· Metastatic Colorectal CancerA Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy
리드: GC녹십자
- 1상완료· Influenza, HumanA Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults
리드: GC녹십자
- 3상완료· Influenza, HumanA Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Subjects Aged 65 Years and Older
리드: GC녹십자
- 3상완료· Immunologic Deficiency SyndromesStudy of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
리드: GC녹십자
- 1상완료· Chronic Hepatitis BA Phase 1 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients
리드: GC녹십자
- 4상완료· Influenza, HumanEvaluate Safety of GCFLU® Administered Intramuscularly in Healthy Vietnamese Volunteer Aged From 3 Years Old
협력: GC녹십자
- 3상완료· InfluenzaA Study to Evaluate the Efficacy and Safety of 'GC3110A(QIV)' in Healthy Children
리드: GC녹십자
- 1상완료· Varicella (Chicken Pox)Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults
리드: GC녹십자
- 2상완료· Hepatitis B InfectionA Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients
리드: GC녹십자
- 해당없음완료· Helicobacter Pylori InfectionCompare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea
협력: 종근당, GC녹십자
- 3상완료· Immune ThrombocytopeniaAn Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia
리드: GC녹십자
- 3상완료· Bacterial InfectionsTo Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults
리드: GC녹십자
- 3상완료· Prophylaxis Against InfluenzaTo Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC3102C' Administered Intramuscularly in Healthy Adults
리드: GC녹십자
- 3상완료· Chronic Fatigue SyndromeInvestigator Initiated Clinical Study to Explore the Efficacy and Safety of Human Placenta Hydrolysate in the Chronic Fatigue Patients
협력: GC녹십자
- 4상완료· OsteoarthritisTo Evaluate the Safety of 'Shinbaro Capsule'in Patients With Osteoarthritis
리드: GC녹십자
- 4상완료· Kawasaki DiseaseStudy of Combined Therapy of Aspirin and "IVIG-SN" in Kawasaki Disease
리드: GC녹십자
- 3상완료· Immunologic Deficiency SyndromePhase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency
리드: GC녹십자
- 2/3상완료· Bacterial InfectionsTo Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Children
리드: GC녹십자
- 1상완료· Healthy VolunteerTo Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Erythropoietin
리드: GC녹십자
- 1상완료· Malignant LymphomasAllogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor
협력: GC녹십자
- 1/2상완료· Mucopolysaccharidosis IITo Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients
리드: GC녹십자
- 1/2상완료· InfluenzaStudy to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult Volunteers
리드: GC녹십자
- 3상완료· Influenza InfectionA Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine
리드: GC녹십자
- 3상완료· InfectionStudy to Evalutate Long-term Immunity of Hantavax in High Risk Population of HFRS
리드: GC녹십자
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.